North America Diabetes Care Devices Market

North America Diabetes Care Devices Market Size

The North America diabetes care devices market was valued at USD 21 billion in 2024 and is projected to grow from USD 23.3 billion in 2025 to USD 66.8 billion by 2034, expanding at a CAGR of 12.4%, according to the latest report published by Global Market Insights Inc. This steady growth is stimulated by various factors such as growing prevalence of diabetes across the North America, rising technological advancements in diabetes care devices, and increased healthcare spending and accessibility. Major companies in the industry include F. Hoffmann-La Roche, Abbott Laboratories, Ascensia Diabetes Care, LifeScan, and Dexcom.

The market increased from USD 15.6 billion in 2021 to USD 19 billion in 2023, largely due to the rising technological advancement in diabetes care devices that have enhanced accuracy convenience and patient engagement innovations such continuous glucose monitors, which was valued at USD 10.9 billion in 2024, smart insulin delivery system, and a integrated mobile platform have not only improved disease management but also expanded the user pays by making care more accessible and personalised. These advancements are accelerating the market growth by making diabetes care smarter, more connected and patients centric.

Rising prevalence of diabetes across regions which have significantly expanded the demand for effective monitoring and management solutions, as more individuals are diagnosed with diabetes the need for advanced care devices such as glucose monitors insulin delivery system and digital health platform continue to grow driving innovation and investment in the region. For instance, in the U.S. alone 38.4 million people of all ages or 11.6 of all population had diabetes. This substantial patient base highlights the urgent need for scalable diabetes care technology. Therefore, this increasing burden of diabetes is accelerating diabetes care devices market growth.

Diabetes care devices refer to a range of medical devices designed to help individuals with diabetes manage their condition effectively. These devices play a crucial role in monitoring blood glucose levels, administering insulin, and overall diabetes management.

North America Diabetes Care Devices Market Trends

• Technology innovation is reshaping diabetes care across North America. Devices such as continuous glucose monitors and closed-loop insulin delivery systems are making management more precise and less invasive for patients.
  
• These advancements are not only improving outcomes but also driving demand. As people seek more convenient and accurate tools, companies are investing heavily in R&D, leading to a surge in new product launches.
  
• Integration with mobile apps and cloud-based platforms is enabling real-time data sharing with healthcare providers. This connectivity is enhancing personalized care and accelerating adoption across hospitals, clinics, and home settings.
  
• For instance, Novo Nordisk offers the FlexTouch, a disposable, pre-filled insulin pen designed with a patient-centric approach. Its ergonomic design requires low injection force, making it easier for people with limited hand strength to use. The pen ensures consistent and accurate dosing and supports various insulin formulations, reflecting the company’s commitment to evolving diabetes care.
  
• Similarly, F. Hoffmann-La Roche manufactures the Accu-Chek line of glucose monitoring devices, including blood glucose meters and insulin delivery systems. Designed for both clinical and home use, these products feature easy-to-read displays, fast and accurate readings, and compatibility with digital health platforms highlighting Roche’s focus on reliable, user-friendly technology.
  
• Thus, these technological advancements are positively contributing to the adoption among the patients, fostering market growth.
  

North America Diabetes Care Devices Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The North America market was valued at USD 15.6 billion in 2021. The market size reached USD 19 billion in 2023, from USD 17.2 billion in 2022. Based on the product, the market is segmented into devices and consumables. The device segment is further segmented into blood glucose monitoring devices and insulin delivery devices. The blood glucose monitoring devices segment dominated the market in 2024, holding the largest share due to the widespread adoption across homecare setting, diagnostic centers, and hospitals. This segment was valued at USD 8.5 billion in 2024 and is projected to reach USD 32.7 billion by 2034, growing at a CAGR of 14.7%. In comparison, the insulin delivery devices segment, valued at USD 6.1 billion in 2024, is expected to grow to USD 16.1 billion by 2034.

• Blood glucose monitoring devices help individuals with diabetes track and manage their blood sugar levels over time. This segment includes self-monitoring tools such as blood glucose meters, continuous glucose monitors (CGMs), testing strips, and lancets.
  
• It dominates the diabetes care monitoring market due to its widespread adoption, ease of use, and essential role in disease management. Rising diabetes prevalence, growing awareness, and ongoing technological advancements continue to drive demand for accurate and user-friendly solutions.
  
• The integration of digital platforms and mobile apps has further enhanced real-time data sharing with healthcare providers, enabling more personalized care. Innovations in sensor technology and non-invasive methods are also expected to fuel future market growth.
  
• For example, Abbott Laboratories offers a comprehensive range under its FreeStyle brand. This includes traditional blood glucose monitors such as FreeStyle Lite, Freedom Lite, and Optium/Precision Neo, as well as the FreeStyle Libre CGM series, which features arm-worn sensors lasting up to 14 days.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the North America diabetes care devices market is segmented into hospitals, ambulatory surgical centers, diagnostic centers, homecare, and other end users. The home care segment accounted for the market share of 43.9% in 2024.

• Many people with diabetes prefer to self-manage their condition at home due to the comfort and flexibility it offers. Home monitoring reduces clinic visits, saving time and easing anxiety.
  
• Easy-to-use devices such as glucometers and wearable monitors support this shift, allowing individuals to track their condition and make informed decisions about diet, medication timing, and physical activity.
  
• For example, Ascensia Diabetes Care offers the Contour Next blood glucose meter, known for its high accuracy, fast results, and user-friendly interface. Paired with digital apps, it enables users to easily track and share glucose data, making it a reliable tool for both daily and long-term management.
  
• As a result, the growing preference for home-based diabetes care especially among the elderly is driving strong growth in the North American home-use diabetes devices market.

Looking for region specific data?

Download Free PDF

U.S. Diabetes Care Devices Market

The U.S. diabetes care devices market was valued at USD 14.3 billion and USD 15.8 billion in 2021 and 2022, respectively. In 2024 the market size reached USD 19.3 billion from USD 17.5 billion in 2023.

• Increased spending on healthcare, along with improved access and awareness, is driving growth in the diabetes care devices market. As investments from both government and private sectors expand healthcare infrastructure, diagnostics, and treatments, access to advanced diabetes management tools becomes more widespread.
  
• Devices such as continuous glucose monitors, insulin pumps, and smart insulin pens are becoming more available and affordable, enabling broader adoption across the population. As healthcare systems grow, so does the demand for effective diabetes care solutions, fueling overall market expansion.
  
• For instance, in 2023, U.S. health spending rose by 7.5%, reaching USD 4.9 trillion or USD 14,570 per capita. This marks the highest growth rate since 2003, excluding the exceptional spike in 2020 due to the COVID-19 pandemic.
  
• Such a significant increase reflects a strong commitment to improving medical services and access, directly supporting the adoption of diabetes care technologies.
  
• Therefore, the surge in healthcare spending and accessibility is not only expanding the reach of diabetes care devices but also accelerating innovation and market growth.
  
  

Canada Diabetes Care Devices Market

Canada diabetes care devices market accounted for USD 1.7 billion in 2024 and is anticipated to show lucrative growth over the forecast period.

• The rising prevalence of diabetes in Canada is significantly driving demand for diabetes care devices. With both type 1 and type 2 cases increasing, continuous monitoring and effective management have become essential.
  
• Devices such as continuous glucose monitors, insulin pumps, and smart glucose meters offer the accuracy and convenience needed to manage these conditions effectively.
  
• Canada currently has an estimated 5.8 million individuals living with diabetes nearly 15% of the population. Of these, over 4 million are diagnosed, accounting for 10%. These figures highlight the urgent need to expand access to advanced diabetes care technologies to support early detection, improve outcomes, and reduce long-term complications.
  
• As the burden of diabetes grows, so does the demand for home-use devices such as glucometers for regular glucose monitoring, further fuelling market growth.
  

North America Diabetes Care Devices Market Share

• Major companies such as F. Hoffmann-La Roche, Abbott Laboratories, Ascensia Diabetes Care, LifeScan, and Dexcom hold a leading position in the North America diabetes care devices market. Their dominance is backed by broad product portfolios, strong distribution networks, regulatory approvals, and ongoing innovation. Among them, Dexcom stands out for its advanced continuous glucose monitoring systems that are widely used across various care settings, giving it a competitive edge.
  
• In addition to hospitals and clinics, the rising demand for home-based diabetes care devices is opening new avenues for both established and emerging companies. Moreover, consumer preference for convenience, faster results, and privacy is driving growth in this segment. Additionally, innovations in wearable monitors and app-connected devices are making homecare solutions more accessible and effective.
  
• Emerging players in the diabetes care space are adopting diverse strategies to gain market share. These include focusing on next-gen technologies such as smart insulin pens, integrated mobile health platforms, and AI-powered glucose tracking. Many are targeting personalized diabetes management and forming strategic partnerships with clinics, tech firms, and research institutions to overcome cost and compliance barriers.
  

North America Diabetes Care Devices Market Companies

Few of the prominent players operating in the North America diabetes care devices industry include:

• Abbott Laboratories
• ARKRAY
• Ascensia Diabetes Care
• B. Braun Melsungen
• Becton, Dickinson and Company
• BIONIME
• DarioHealth
• Dexcom
• Dr. Reddy’s Laboratories
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Insulet
• LifeScan Inc
• Medtronic
• Nova Biomedical
• Novo Nordisk
• Platinum Equity Advisors
• Sanofi
• Sinocare
• Tandem Diabetes Care
  
  
• Abbott Laboratories

Abbott Laboratories is a healthcare company recognized for its innovative contributions to diabetes care through advanced monitoring technologies. The company focuses on developing user-friendly, accurate, and connected solutions that support both clinical and personal diabetes management. Abbott emphasizes accessibility and real-time tracking to help individuals manage their condition more effectively. Its flagship product, the FreeStyle Libre system, is a continuous glucose monitor that provides real-time readings without routine fingersticks, offering convenience and improved control for users.

• B. Braun Melsungen

B. Braun Melsungen is a healthcare company known for its contributions to diabetes care through reliable and clinically focused solutions. The company emphasizes safety, precision, and ease of use in its product designs, catering to both professional and personal care settings. B. Braun integrates its diabetes care tools with broader patient management systems to support consistent monitoring and treatment. Its product, the Omnitest blood glucose meter, offers accurate readings and a simple interface, making it suitable for everyday use by individuals managing diabetes.

• Medtronic

Medtronic is a healthcare company known for its advanced diabetes care solutions that combine technology, precision, and patient-centered design. The company focuses on developing automated insulin delivery systems and smart injection tools that simplify diabetes management. Medtronic’s offerings support both clinical and personal use, helping users maintain better glucose control with less effort. Its flagship product, the MiniMed 780G system, features automated insulin adjustments every five minutes and meal detection technology, making it one of the most intuitive and responsive insulin pump systems available.

North America Diabetes Care Devices Industry News

• In July 2024, DarioHealth announced the acquisition of Twill, a digital health company focused on behavioral and chronic condition management. The acquisition aimed to expand Dario’s capabilities in delivering integrated care solutions for diabetes and emotional health. By combining Twill’s expertise in digital therapeutics with Dario’s data-driven platform, the company positioned itself for significant growth in revenue and margins, while enhancing its ability to support holistic chronic disease management.
  
• In September 2023, Abbott Laboratories completed the acquisition of Bigfoot Biomedical, a company specializing in smart insulin management systems. This strategic move strengthened Abbott’s diabetes care portfolio, particularly enhancing its widely used FreeStyle Libre continuous glucose monitoring (CGM) technology.
  

The North America diabetes care devices market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Device
  • Blood glucose monitoring devices
    • Self-monitoring blood glucose meters
    • Continuous glucose monitors
  • Insulin delivery devices
    • Insulin pumps
      • Tubed pumps
      • Tubeless pumps
    • Pens
      • Reusable
      • Disposable
    • Other insulin delivery devices 
• Consumables
  • Testing strips
  • Lancets
  • Pen needles
    • Standard
    • Safety
  • Syringes
  • Insulin pumps consumables

Market, By End Use

• Hospital
• Ambulatory surgical centers        
• Diagnostic centers
• Homecare
• Other end use

The above information is provided for the following countries:

• U.S.
• Canada